The compound, CuATSM, is currently in Phase II/III clinical trials after repeated preclinical reports that CuATSM treatment slows disease progression and improves survival in several mouse models of SOD1-associated ALS. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.